Blueprint Medicines (BPMC) News Today $91.93 -2.42 (-2.56%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Blueprint Medicines (NASDAQ:BPMC) Issues Earnings ResultsBlueprint Medicines (NASDAQ:BPMC - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%.February 21 at 11:20 AM | marketbeat.comBlueprint Medicines (BPMC) Gets a Hold from BarclaysFebruary 18 at 7:16 AM | markets.businessinsider.comBlueprint Medicines (BPMC) Gets a Hold from BarclaysFebruary 18 at 7:16 AM | markets.businessinsider.comQ1 Earnings Forecast for BPMC Issued By Leerink PartnrsFebruary 17, 2025 | americanbankingnews.comBlueprint Medicines' (BPMC) "Market Outperform" Rating Reiterated at JMP SecuritiesFebruary 17, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for BPMC Q1 Earnings?Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Blueprint Medicines in a research note issued on Thursday, February 13th. Leerink Partnrs analyst A. Berens forecasts that the biotechnoFebruary 17, 2025 | marketbeat.comBlueprint Medicines (NASDAQ:BPMC) Cut to "Sell" at StockNews.comFebruary 17, 2025 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Short Interest Down 18.1% in JanuaryBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 4,210,000 shares, a decline of 18.1% from the January 15th total of 5,140,000 shares. Based on an average trading volume of 764,600 shares, the days-to-cover ratio is presently 5.5 days.February 16, 2025 | marketbeat.comStephens Inc. AR Purchases New Holdings in Blueprint Medicines Co. (NASDAQ:BPMC)Stephens Inc. AR acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,684 shares of the biotechnology company's stock, valued at approximaFebruary 16, 2025 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)February 16, 2025 | americanbankingnews.comBlueprint Medicines' (BPMC) Buy Rating Reiterated at HC WainwrightFebruary 16, 2025 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Rating Lowered to "Sell" at StockNews.comStockNews.com cut Blueprint Medicines from a "hold" rating to a "sell" rating in a report on Friday.February 15, 2025 | marketbeat.comBlueprint Medicines Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 15, 2025 | uk.finance.yahoo.comBlueprint Medicines (NASDAQ:BPMC) Given Market Outperform Rating at JMP SecuritiesJMP Securities restated a "market outperform" rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Friday.February 15, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC)HC Wainwright reaffirmed a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday.February 15, 2025 | marketbeat.comMorgan Stanley Sticks to Their Hold Rating for Blueprint Medicines (BPMC)February 14, 2025 | markets.businessinsider.comWells Fargo Remains a Buy on Blueprint Medicines (BPMC)February 14, 2025 | markets.businessinsider.comWedbush Reiterates "Outperform" Rating for Blueprint Medicines (NASDAQ:BPMC)Wedbush reissued an "outperform" rating and issued a $128.00 target price (up previously from $124.00) on shares of Blueprint Medicines in a report on Thursday.February 14, 2025 | marketbeat.comBlueprint Medicines Corp (BPMC) Q4 2024 Earnings Call Highlights: Record Growth and Strategic ...February 14, 2025 | finance.yahoo.comBlueprint Medicines should be bought on any weakness, says StifelFebruary 13, 2025 | markets.businessinsider.comEarnings call transcript: Blueprint Medicines Q4 2024 misses EPS estimatesFebruary 13, 2025 | msn.comBlueprint Medicines projects $680M-$710M AYVAKIT revenue in 2025 with 45% growthFebruary 13, 2025 | msn.comBlueprint Medicines selloff to be short-lived, says OppenheimerFebruary 13, 2025 | markets.businessinsider.comBlueprint Medicines Corporation (BPMC) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | seekingalpha.comBlueprint Medicines (NASDAQ:BPMC) Shares Gap Down - Here's What HappenedBlueprint Medicines (NASDAQ:BPMC) Shares Gap Down - What's Next?February 13, 2025 | marketbeat.comBlueprint Medicines Corporation 2024 Q4 - Results - Earnings Call PresentationFebruary 13, 2025 | seekingalpha.comBlueprint Medicines' (BPMC) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday.February 13, 2025 | marketbeat.comBlueprint Medicines reports Q4 EPS (79c), consensus (71c)February 13, 2025 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC)February 13, 2025 | markets.businessinsider.comBlueprint Medicines Reports Fourth Quarter and Full Year 2024 ResultsFebruary 13, 2025 | prnewswire.comValues First Advisors Inc. Acquires 3,655 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)Values First Advisors Inc. lifted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 277.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,970 shares of the biotechnology company's stock after buying an additionFebruary 13, 2025 | marketbeat.comBlueprint Medicines (BPMC) to Release Quarterly Earnings on ThursdayBlueprint Medicines (NASDAQ:BPMC) will be releasing earnings before the market opens on Thursday, February 20, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662650)February 13, 2025 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)February 12, 2025 | markets.businessinsider.comWhat is Leerink Partnrs' Estimate for BPMC FY2025 Earnings?February 12, 2025 | americanbankingnews.comFY2025 Earnings Forecast for BPMC Issued By Leerink PartnrsBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Research analysts at Leerink Partnrs cut their FY2025 EPS estimates for Blueprint Medicines in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earninFebruary 10, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook of BPMC FY2026 EarningsBlueprint Medicines Co. (NASDAQ:BPMC - Free Report) - Equities research analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Blueprint Medicines in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the biotechnoloFebruary 7, 2025 | marketbeat.comBlueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025February 5, 2025 | prnewswire.comJennison Associates LLC Buys Shares of 360,208 Blueprint Medicines Co. (NASDAQ:BPMC)Jennison Associates LLC bought a new position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 360,208 shares of the biotechnology company's stock, valued at approximately $31,417,February 5, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $129.00JPMorgan Chase & Co. lifted their target price on Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a report on Tuesday.February 4, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Sees Significant Increase in Short InterestBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) saw a large growth in short interest in January. As of January 15th, there was short interest totalling 5,100,000 shares, a growth of 12.6% from the December 31st total of 4,530,000 shares. Based on an average trading volume of 643,900 shares, the days-to-cover ratio is presently 7.9 days.February 3, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of "Moderate Buy" from AnalystsBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twenty analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twelve have iJanuary 30, 2025 | marketbeat.comBlueprint Medicines price target raised to $119 from $109 at Piper SandlerJanuary 27, 2025 | markets.businessinsider.comBlueprint Medicines stock target raised to $119 by Piper SandlerJanuary 27, 2025 | msn.comBlueprint Medicines (NASDAQ:BPMC) Given New $119.00 Price Target at Piper SandlerPiper Sandler upped their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research note on Monday.January 27, 2025 | marketbeat.comBlueprint Medicines CEO sells shares worth $159,407January 24, 2025 | msn.comBlueprint Medicines director Jeffrey Albers sells shares for $1.66 millionJanuary 24, 2025 | msn.comBlueprint Medicines Co. (NASDAQ:BPMC) CEO Kate Haviland Sells 1,446 SharesJanuary 24, 2025 | insidertrades.comBlueprint Medicines Co. (NASDAQ:BPMC) CEO Sells $159,407.04 in StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) CEO Kate Haviland sold 1,446 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares in the company, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.January 23, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) COO Sells $250,458.36 in StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.14, for a total value of $250,458.36. Following the sale, the chief operating officer now owns 67,109 shares in the company, valued at $7,391,385.26. This represents a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.January 23, 2025 | marketbeat.comBlueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,660,584.33 in StockBlueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 15,161 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $109.53, for a total value of $1,660,584.33. Following the transaction, the director now owns 152,396 shares in the company, valued at approximately $16,691,933.88. This trade represents a 9.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.January 23, 2025 | marketbeat.com Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Media Mentions By Week BPMC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BPMC News Sentiment▼0.220.60▲Average Medical News Sentiment BPMC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BPMC Articles This Week▼217▲BPMC Articles Average Week Get Blueprint Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TEVA News Today SMMT News Today GMAB News Today ITCI News Today VTRS News Today MRNA News Today RDY News Today PCVX News Today SRPT News Today QGEN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BPMC) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPMC Stock Alerts